Editas Medicine (EDIT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
Meeting called to order by the Chair, held in an all-virtual format to ensure equal participation rights for all stockholders.
Introductions included board members, senior management, independent auditor, and Inspector of Election.
Rules of conduct and confirmation of proper notice to stockholders were addressed.
Board and executive committee updates
Attendance included all directors, CEO, CFO, Chief Scientific Officer, General Counsel, and other senior leaders.
Shareholder proposals
Three proposals: election of two Class I directors, advisory vote on executive compensation, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Editas Medicine
- Pivoting to in vivo gene editing, with proof of concept achieved and cash runway to Q2 2027.EDIT
Strategy Update9 Jul 2026 - In vivo gene editing and reni-cel partnership drive strategic focus, with strong financial runway.EDIT
Stifel 2024 Healthcare Conference9 Jul 2026 - Reniz-cel shows strong efficacy as the company advances in vivo editing and IP monetization strategies.EDIT
Morgan Stanley 22nd Annual Global Healthcare Conference8 Jul 2026 - Q2 net loss widened to $67.6M as R&D spending surged; cash runway extends into 2026.EDIT
Q2 20248 Jul 2026 - CRISPR-based LDLR upregulation shows 90% LDL reduction, with human trials set for 2026.EDIT
Evercore ISI 8th Annual HealthCONx Conference30 Jun 2026 - EDIT-401 shows durable 90% LDL and Lp(a) reduction, with clinical trials starting in 2024.EDIT
Jefferies Global Healthcare Conference 20264 Jun 2026 - EDIT-401 achieved >90% LDL-C reduction preclinically, targeting major unmet needs in hyperlipidemia.EDIT
Corporate presentation27 May 2026 - Net loss narrowed to $25M as EDIT-401 advanced and cash runway extends into Q3 2027.EDIT
Q1 20265 May 2026 - Proxy covers director elections, pay, auditor change, and strong governance with ESG focus.EDIT
Proxy filing28 Apr 2026